Clinical characteristics of included subjects
Subjects . | Sex . | Age, y . | CD4, cells/mm3 . | VL, copies/mL . | Treatment . | Stage* . | Duration, y† . |
|---|---|---|---|---|---|---|---|
| HIVprog 1‡ | M | 35 | 470 | 1 800 | None | A1 | >2 |
| HIVprog 2 | M | 42 | 464 | 241 861 | None | A1 | > 2 |
| HIVprog 3 | M | 23 | 282 | > 100 000 | None | A1 | > 2 |
| HIVprog 4 | F | 42 | 303 | 107 204 | None | A1 | > 2 |
| HIVprog 5 | M | 37 | 136 | 405 700 | None | C | > 2 |
| HIVprog 6 | M | 47 | 391 | 78 589 | None | A2 | > 2 |
| HIVnp 1 | F | 41 | 410 | 4 300 | None | A1 | 14 |
| HIVnp 2 | M | 36 | 510 | 300 | None | A1 | 15 |
| HIVnp 3 | M | 43 | 760 | < 50 | None | A1 | 15 |
| HIVnp 4 | F | 27 | 920 | < 50 | None | A1 | > 5 |
| HIVnp 5 | F | 34 | 620 | 200 | None | A1 | > 5 |
| Uninfected 1 | M | 37 | — | — | — | — | — |
| Uninfected 2 | F | 42 | — | — | — | — | — |
| Uninfected 3 | M | 39 | — | — | — | — | — |
| Uninfected 4 | M | 34 | — | — | — | — | — |
| Uninfected 5 | M | 28 | — | — | — | — | — |
Subjects . | Sex . | Age, y . | CD4, cells/mm3 . | VL, copies/mL . | Treatment . | Stage* . | Duration, y† . |
|---|---|---|---|---|---|---|---|
| HIVprog 1‡ | M | 35 | 470 | 1 800 | None | A1 | >2 |
| HIVprog 2 | M | 42 | 464 | 241 861 | None | A1 | > 2 |
| HIVprog 3 | M | 23 | 282 | > 100 000 | None | A1 | > 2 |
| HIVprog 4 | F | 42 | 303 | 107 204 | None | A1 | > 2 |
| HIVprog 5 | M | 37 | 136 | 405 700 | None | C | > 2 |
| HIVprog 6 | M | 47 | 391 | 78 589 | None | A2 | > 2 |
| HIVnp 1 | F | 41 | 410 | 4 300 | None | A1 | 14 |
| HIVnp 2 | M | 36 | 510 | 300 | None | A1 | 15 |
| HIVnp 3 | M | 43 | 760 | < 50 | None | A1 | 15 |
| HIVnp 4 | F | 27 | 920 | < 50 | None | A1 | > 5 |
| HIVnp 5 | F | 34 | 620 | 200 | None | A1 | > 5 |
| Uninfected 1 | M | 37 | — | — | — | — | — |
| Uninfected 2 | F | 42 | — | — | — | — | — |
| Uninfected 3 | M | 39 | — | — | — | — | — |
| Uninfected 4 | M | 34 | — | — | — | — | — |
| Uninfected 5 | M | 28 | — | — | — | — | — |
VL indicates viral load; —, not applicable.
Disease stage, according to CDC classification. In addition, all biopsies from the HIVprog, but none from the HIVnp, were graded as follicular hyperplasia, which is prognostic of disease progression.23
Documented duration of HIV-1 infection, defined as years of known seropositivity.
Although his CD4 counts was relatively high and his VL was low at the time of biopsy, HIVprog 1 did not meet the definition of the nonprogressors (ie, stable CD4 counts and low VL for a minimum of 5 years). Moreover, subsequent follow-up of HIVprog 1 has shown a pattern toward progression, with a steady VL increase (7 600 and 22 000 copies/mL at 3 and 5.5 years after biopsy, respectively).